tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sagimet announces results from Phase 1 PK trial of denifanstat, resmetirom
PremiumThe FlySagimet announces results from Phase 1 PK trial of denifanstat, resmetirom
2M ago
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences
Premium
Ratings
Strategic Licensing and Pipeline Advancements Drive Buy Rating for Sagimet Biosciences
2M ago
Sagimet Biosciences enters global license agreement with TAPI
Premium
Company Announcements
Sagimet Biosciences enters global license agreement with TAPI
2M ago
Sagimet Biosciences price target raised to $35 from $33 at Citizens JMP
PremiumThe FlySagimet Biosciences price target raised to $35 from $33 at Citizens JMP
3M ago
Sagimet Biosciences Reports Q3 2025 Financial Results
Premium
Company Announcements
Sagimet Biosciences Reports Q3 2025 Financial Results
3M ago
Optimistic Buy Rating for Sagimet Biosciences Driven by Promising Clinical Progress and Strong Financial Position
Premium
Ratings
Optimistic Buy Rating for Sagimet Biosciences Driven by Promising Clinical Progress and Strong Financial Position
3M ago
Sagimet Biosciences announces denifanstat met all primary, secondary endpoints
PremiumThe FlySagimet Biosciences announces denifanstat met all primary, secondary endpoints
3M ago
Sagimet Biosciences Highlights Drug Development Success
Premium
Company Announcements
Sagimet Biosciences Highlights Drug Development Success
3M ago
Sagimet Biosciences initiated with a Buy at Clear Street
Premium
The Fly
Sagimet Biosciences initiated with a Buy at Clear Street
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100